Use of the Biopharmaceutical Classification System in Early Drug Development
Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 1
Abstract
The Biopharmaceutics Classification System (BCS) is not only a useful tool for obtaining waivers for in-vivo bioequivalence studies but also for decision making in the discovery and early development of new drugs. Measurement of solubility and permeability in the discovery/development settings is described. These data can be utilized for the preliminary BCS classification of pipeline compounds. A decision tree is described in the prioritization of salt and polymorph screening studies prior to in vivo studies in animals. For BCS class 1 and 3 compounds, polymorphism is less likely to impact on bioavailability. The polymorph screening study may be postponed after animal studies. The BCS classification can also be used in the design of animal and human formulations. A BCS-based animal formulation development decision tree is presented. A compound is triaged based on a series of decision points into one of the five formulation strategies. Human formulation has different requirements than animal formulation. A comparison between animal and human formulation strategies is presented. In conclusion, for non-BCS 1 compounds, the right-first-time polymorph and formulation selection ensures consistent pharmacokinetic performance and avoids bridging BA/BE studies. It is in line with FDA’s initiative to reduce R&D cycle time through quality by design for pharmaceutical products.
Authors and Affiliations
M. Sherry Ku
Keywords
Related Articles
- EP ID EP681533
- DOI 10.1208/s12248-008-9020-0
- Views 78
- Downloads 0
Dietary Flavonoids Modulate CYP2C to Improve Drug Oral Bioavailability and Their Qualitative/Quantitative Structure–Activity Relationship
This study aims to improve the drug oral bioavailability by co-administration with flavonoid inhibitors of the CYP2C isozyme and to establish qualitative and quantitative (QSAR) structure–activity relationships (...
Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology
Current efforts to identify protein biomarkers of disease use mainly mass spectrometry (MS) to analyze tissue and blood specimens. The low-molecular-weight “peptidome” is an attractive information archive...
Challenges and issues in veterinary pharmacology and animal health 2004—Preface
Strategic Approaches to Optimizing Peptide ADME Properties
Development of peptide drugs is challenging but also quite rewarding. Five blockbuster peptide drugs are currently on the market, and six new peptides received first marketing approval as new molecular entities in 2012....
Lipidomics Revealed Idiopathic Pulmonary Fibrosis-Induced Hepatic Lipid Disorders Corrected with Treatment of Baicalin in a Murine Model
The online version of this article (doi:10.1208/s12248-014-9714-4) contains supplementary material, which is available to authorized users.